Suven Life Sciences is currently trading at Rs. 210.00, up by 5.40 points or 2.64% from its previous closing of Rs. 204.60 on the BSE.
The scrip opened at Rs. 206.30 and has touched a high and low of Rs. 221.00 and Rs. 202.05 respectively. So far 1,96,000 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 308.70 on 05-Oct-2015 and a 52 week low of Rs. 144.35 on 19-Feb-2016.
Last one week high and low of the scrip stood at Rs. 308.70 and Rs. 144.35 respectively. The current market cap of the company is Rs. 2,667.20 crore.
The promoters holding in the company stood at 60.00%, while Institutions and Non-Institutions held 7.62% and 32.38% respectively.
Suven Life Sciences, an ISO 9001, ISO 14001 and OHSAS 18001 company has undergone US FDA renewal inspection at their facility in Pashamylaram near Hyderabad for the manufacture and supply of active pharmaceutical ingredients (bulk drugs), intermediates and formulations under cGMP during April 4 to April 14, 2016.
Based on the inspection and the review thereafter US-FDA has concluded that the inspection is ‘closed’ under 21CFR20.64 (d) (3) and the agency has issued an Establishment Inspection Report (EIR) for Suven facility at Pashamylaram dtd July 15, 2016. So far Suven Life Sciences has filed 19 DMF’s and 4 ANDA’s from this facility which is FDA complaint under cGMP and continued after renewal inspection.
